Added to YB: 2026-03-03
Pitch date: 2026-03-01
GILD [neutral]
Gilead Sciences, Inc.
+1.46%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Market Cap
$184.9B
Pitch Price
$147.87
Price Target
155.00 (+4%)
Dividend
2.20%
EV/EBITDA
13.41
P/E
21.97
EV/Sales
6.72
Sector
Biotechnology
Category
growth
Buying Opportunities - Gilead Sciences, Inc.
GILD (update): Up 2x since 2024 recommendation. Q4 in-line: HIV +6% YoY, liver disease +17%. Acquired Arcello for $7.8B to lead cell therapy (anito-cell for relapsed/refractory multiple myeloma, next-gen CAR-T). Accretive from 2028. Fair value raised to $155 from $125 on growth + M&A upside. Trading at $149, fairly valued.
Read full article (1 min)